CoChat
Sign Up
Cited by 25MicroRNA in disease regulationHepatocellular Carcinoma Treatment and PrognosisCancer-related molecular mechanisms research

MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes

Open access
Elemeery, Moustafa Nouh, Mohamed, Marwa Anwar, Madkour, Marwa Ahmed, Shamseya, Mohammed Mohammed, Issa, Noha Mahmoud, Badr, Ahmed Noah, Ghareeb, Doaa Ahmed, Pan, Cheol-Ho·2019·World Journal of Gastroenterology
DOI 10.3748/wjg.v25.i42.6322PMC PMC6861851
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Nonalcoholic steatohepatitis-related cirrhosis is one of the liver complications in type 2 diabetes mellitus (T2DM) and reported to be a risk factor for developing hepatocellular carcinoma (HCC). A reliable screening biomarker of liver cirrhosis (LC) and HCC among T2DM patients is important to reduce the morbidity and mortality of this disease. MicroRNA (miRNA) is considered a key player in HCC and T2DM, and it might be a hidden culprit in diabetes-associated HCC, making it a promising reliable prognostic tool. AIM: To investigate the signature of serum miRNAs as early biomarkers for the screening of HCC among diabetic patients. METHODS: Expression profiles of miRNAs in serum samples of diabetic LC and diabetic HCC patients were assessed using Illumina sequencing; then, RT-qPCR was used to validate significantly altered miRNAs between the two groups. Candidate miRNAs were tested in serum samples of 200 T2DM patients, 270 LC patients, 200 HCC patients, and 225 healthy control subjects. Additionally, receiver operating characteristic (ROC) analysis, with area under the curve (AUC), was performed to assess the diagnostic performance of the screened miRNAs for discriminating HCC from LC and nonmalignant patients (LC + T2DM). RESULTS: LC-positive T2DM patients. Two miRNAs (miR-34a, miR-221) were significantly up-regulated and five miRNAs (miR-16, miR-23-3p, miR-122-5p, miR-198, miR-199a-3p) were significantly down-regulated in HCC compared to LC patients. Analysis of ROC curve demonstrated that the combination of these seven miRNAs can be used as a reliable biomarker for detection of HCC in diabetic patients, as it could identify HCC with high diagnostic accuracy in diabetic LC patients (AUC = 0.993) and in diabetic nonmalignant patients (AUC = 0.961). CONCLUSION: the miRNA regulatory pathway.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3748/wjg.v25.i42.6322

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-23 can screen liver cirrhosis and HCC in patients with T2DM.

    “it can also screen liver cirrhosis (LC) and HCC in patients with T2DM.”

    From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [73]

    The Results section ('Testing the efficacy of studied miRNAs in diagnosis'; page not provided) reports that miR-23b-3p distinguished HCC from diabetic nonmalignant patients, including those with liver cirrhosis. The Discussion proposes it as a possible biomarker for T2DM-associated HCC diagnosis. The paper does not establish miR-23b-3p as a screening test for liver cirrhosis itself, and describes the seven-miRNA panel—not miR-23b-3p alone—as a reliable HCC screening biomarker. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 63

  1. [1]American Diabetes Association 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019 Diabetes Care 2019 42 S13 S28 30559228
  2. [2]Huang TS Lin CL Lu MJ Yeh CT Liang KH Sun CC Shyu YC Chien RN Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: A population-based cohort study J Gastroenterol Hepatol 2017 32 1355 1362 27930829
  3. [3]Wang P Kang D Cao W Wang Y Liu Z Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis Diabetes Metab Res Rev 2012 28 109 122 21898753
  4. [4]Fujita K Iwama H Miyoshi H Tani J Oura K Tadokoro T Sakamoto T Nomura T Morishita A Yoneyama H Masaki T Diabetes mellitus and metformin in hepatocellular carcinoma World J Gastroenterol 2016 22 6100 6113 27468203 PMC4945972
  5. [5]Tan Y Ge G Pan T Wen D Chen L Yu X Zhou X Gan J A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus PLoS One 2014 9 e107986 25238238 PMC4169601
  6. [6]Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004 116 281 297 14744438
  7. [8]Elemeery MN Badr AN Mohamed MA Ghareeb DA Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients World J Gastroenterol 2017 23 3864 3875 28638226 PMC5467072
  8. [9]Gao B Ning S Li J Liu H Wei W Wu F Tang Y Feng Y Li K Zhang L Integrated analysis of differentially expressed mRNAs and miRNAs between hepatocellular carcinoma and their matched adjacent normal liver tissues Oncol Rep 2015 34 325 333 26062888
  9. [10]Esquela-Kerscher A Slack FJ Oncomirs - microRNAs with a role in cancer Nat Rev Cancer 2006 6 259 269 16557279
  10. [11]Chen X Ba Y Ma L Cai X Yin Y Wang K Guo J Zhang Y Chen J Guo X Li Q Li X Wang W Zhang Y Wang J Jiang X Xiang Y Xu C Zheng P Zhang J Li R Zhang H Shang X Gong T Ning G Wang J Zen K Zhang J Zhang CY Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases Cell Res 2008 18 997 1006 18766170
  11. [12]Kelly BD Miller N Sweeney KJ Durkan GC Rogers E Walsh K Kerin MJ A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group J Clin Med 2015 4 1369 1379 26239681 PMC4519795
  12. [13]Zhu C Ren C Han J Ding Y Du J Dai N Dai J Ma H Hu Z Shen H Xu Y Jin G A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer Br J Cancer 2014 110 2291 2299 24595006 PMC4007222
  13. [14]Mitchell PS Parkin RK Kroh EM Fritz BR Wyman SK Pogosova-Agadjanyan EL Peterson A Noteboom J O'Briant KC Allen A Lin DW Urban N Drescher CW Knudsen BS Stirewalt DL Gentleman R Vessella RL Nelson PS Martin DB Tewari M Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci USA 2008 105 10513 10518 18663219 PMC2492472
  14. [15]Li Y Jiang Z Xu L Yao H Guo J Ding X Stability analysis of liver cancer-related microRNAs Acta Biochim Biophys Sin (Shanghai) 2011 43 69 78 21173058
  15. [16]Zhang BH Shen CA Zhu BW An HY Zheng B Xu SB Sun JC Sun PC Zhang W Wang J Liu JY Fan YQ Insight into miRNAs related with glucometabolic disorder Biomed Pharmacother 2019 111 657 665 30611990
  16. [17]Lorente-Cebrián S González-Muniesa P Milagro FI Martínez JA MicroRNAs and other non-coding RNAs in adipose tissue and obesity: emerging roles as biomarkers and therapeutic targets Clin Sci (Lond) 2019 133 23 40 30606812
  17. [18]Bruix J Sherman M Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma Hepatology 2005 42 1208 1236 16250051
  18. [19]Forner A Reig ME de Lope CR Bruix J Current strategy for staging and treatment: the BCLC update and future prospects Semin Liver Dis 2010 30 61 74 20175034
  19. [20]Wen Y Han J Chen J Dong J Xia Y Liu J Jiang Y Dai J Lu J Jin G Han J Wei Q Shen H Sun B Hu Z Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma Int J Cancer 2015 137 1679 1690 25845839
  20. [21]Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 2001 25 402 408 11846609
  21. [22]Jiang L Cheng Q Zhang BH Zhang MZ Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China Medicine (Baltimore) 2015 94 e603 25761179 PMC4602462
  22. [23]Ali HEA Abdel Hameed R Effat H Ahmed EK Atef AA Sharawi SK Ali M Abd Elmageed ZY Abdel Wahab AH Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma Clin Res Hepatol Gastroenterol 2017 41 e51 e62 28750770
  23. [24]Ambros V Bartel B Bartel DP Burge CB Carrington JC Chen X Dreyfuss G Eddy SR Griffiths-Jones S Marshall M Matzke M Ruvkun G Tuschl T A uniform system for microRNA annotation RNA 2003 9 277 279 12592000 PMC1370393
  24. [25]Mantovani A Targher G Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease Ann Transl Med 2017 5 270 28758096 PMC5515814
  25. [26]Stigliano R Marelli L Yu D Davies N Patch D Burroughs AK Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC Cancer Treat Rev 2007 33 437 447 17512669
  26. [27]Block T Mehta AS London WT Hepatocellular carcinoma of the liver Cancer Biomark 2010 9 375 383 22112485 PMC13015974
  27. [28]Chang RM Yang H Fang F Xu JF Yang LY MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase Hepatology 2014 60 1251 1263 24825302
  28. [29]Willeit P Skroblin P Moschen AR Yin X Kaudewitz D Zampetaki A Barwari T Whitehead M Ramírez CM Goedeke L Rotllan N Bonora E Hughes AD Santer P Fernández-Hernando C Tilg H Willeit J Kiechl S Mayr M Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes Diabetes 2017 66 347 357 27899485 PMC5248985
  29. [30]Lin CJ Gong HY Tseng HC Wang WL Wu JL miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines Biochem Biophys Res Commun 2008 375 315 320 18692484
  30. [31]Tsai WC Hsu PW Lai TC Chau GY Lin CW Chen CM Lin CD Liao YL Wang JL Chau YP Hsu MT Hsiao M Huang HD Tsou AP MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma Hepatology 2009 49 1571 1582 19296470
  31. [32]Xu J Zhu X Wu L Yang R Yang Z Wang Q Wu F MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway Liver Int 2012 32 752 760 22276989
  32. [33]Jampoka K Muangpaisarn P Khongnomnan K Treeprasertsuk S Tangkijvanich P Payungporn S Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD) Microrna 2018 7 215 222 29848284
  33. [34]Xu J Wu C Che X Wang L Yu D Zhang T Huang L Li H Tan W Wang C Lin D Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis Mol Carcinog 2011 50 136 142 21229610
  34. [35]Zekri AN Youssef AS El-Desouky ED Ahmed OS Lotfy MM Nassar AA Bahnassey AA Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection Tumour Biol 2016 37 12273 12286 27271989
  35. [36]Qi P Cheng SQ Wang H Li N Chen YF Gao CF Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection PLoS One 2011 6 e28486 22174818 PMC3234251
  36. [37]Hung CH Hu TH Lu SN Kuo FY Chen CH Wang JH Huang CM Lee CM Lin CY Yen YH Chiu YC Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus Int J Cancer 2016 138 714 720 26264553
  37. [38]Giordano S Columbano A MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology 2013 57 840 847 23081718
  38. [39]Zhao S Li T Li J Lu Q Han C Wang N Qiu Q Cao H Xu X Chen H Zheng Z miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway Diabetologia 2016 59 644 654 26687158
  39. [40]Cao J Liu J Long J Fu J Huang L Li J Liu C Zhang X Yan Y microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2 Biomed Pharmacother 2017 89 642 650 28262617
  40. [41]Liu Q Yu Z Yuan S Xie W Li C Hu Z Xiang Y Wu N Wu L Bai L Li Y Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer Oncotarget 2017 8 13048 13058 28055956 PMC5355076
  41. [42]He RQ Wu PR Xiang XL Yang X Liang HW Qiu XH Yang LH Peng ZG Chen G Downregulated miR-23b-3p expression acts as a predictor of hepatocellular carcinoma progression: A study based on public data and RT-qPCR verification Int J Mol Med 2018 41 2813 2831 29484429 PMC5846654
  42. [43]Rong M Chen G Dang Y Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro BMC Cancer 2013 13 21 23320393 PMC3551704
  43. [44]Liu Z Wang C Jiao X Zhao S Liu X Wang Y Zhang J miR-221 promotes growth and invasion of hepatocellular carcinoma cells by constitutive activation of NFκB Am J Transl Res 2016 8 4764 4777 27904678 PMC5126320
  44. [45]Garofalo M Di Leva G Romano G Nuovo G Suh SS Ngankeu A Taccioli C Pichiorri F Alder H Secchiero P Gasparini P Gonelli A Costinean S Acunzo M Condorelli G Croce CM miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation Cancer Cell 2009 16 498 509 19962668 PMC2796583
  45. [46]Garofalo M Romano G Di Leva G Nuovo G Jeon YJ Ngankeu A Sun J Lovat F Alder H Condorelli G Engelman JA Ono M Rho JK Cascione L Volinia S Nephew KP Croce CM EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers Nat Med 2011 18 74 82 22157681 PMC3467100
  46. [47]Giglio S Vecchione A c-Met and miRs in Cancer Biomedicines 2015 3 32 44 28536397 PMC5344231
  47. [48]Li Y Guessous F Zhang Y Dipierro C Kefas B Johnson E Marcinkiewicz L Jiang J Yang Y Schmittgen TD Lopes B Schiff D Purow B Abounader R MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes Cancer Res 2009 69 7569 7576 19773441 PMC2756313
  48. [49]Migliore C Petrelli A Ghiso E Corso S Capparuccia L Eramo A Comoglio PM Giordano S MicroRNAs impair MET-mediated invasive growth Cancer Res 2008 68 10128 10136 19074879
  49. [50]Sun TY Xie HJ Li Z Kong LF Gou XN Li DJ Shi YJ Ding YZ miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma Am J Transl Res 2017 9 103 114 28123637 PMC5250707
  50. [51]Wu G Li Z Wang Y Ju X Huang R miR-34a Inhibits Cell Proliferation by Targeting SATB2 in Hepatocellular Carcinoma Biomed Res Int 2018 2018 2863902 30627547 PMC6304654
  51. [52]Cheng J Zhou L Xie QF Xie HY Wei XY Gao F Xing CY Xu X Li LJ Zheng SS The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells Proteomics 2010 10 1557 1572 20186752
  52. [53]Guan J Liu Z Xiao M Hao F Wang C Chen Y Lu Y Liang J MicroRNA-199a-3p inhibits tumorigenesis of hepatocellular carcinoma cells by targeting ZHX1/PUMA signal Am J Transl Res 2017 9 2457 2465 28559996 PMC5446528
  53. [54]Li YB Wu Q Liu J Fan YZ Yu KF Cai Y miR199a3p is involved in the pathogenesis and progression of diabetic neuropathy through downregulation of SerpinE2 Mol Med Rep 2017 16 2417 2424 28677735 PMC5547973
  54. [55]Kim S Lee UJ Kim MN Lee EJ Kim JY Lee MY Choung S Kim YJ Choi YC MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2) J Biol Chem 2008 283 18158 18166 18456660
  55. [56]Huang WT Wang HL Yang H Ren FH Luo YH Huang CQ Liang YY Liang HW Chen G Dang YW Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study Onco Targets Ther 2016 9 5163 5180 27578984 PMC5001667
  56. [57]Elfimova N Sievers E Eischeid H Kwiecinski M Noetel A Hunt H Becker D Frommolt P Quasdorff M Steffen HM Nürnberg P Büttner R Teufel A Dienes HP Drebber U Odenthal M Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration Biochim Biophys Acta 2013 1833 1190 1198 23391410
  57. [58]Calin GA Cimmino A Fabbri M Ferracin M Wojcik SE Shimizu M Taccioli C Zanesi N Garzon R Aqeilan RI Alder H Volinia S Rassenti L Liu X Liu CG Kipps TJ Negrini M Croce CM MiR-15a and miR-16-1 cluster functions in human leukemia Proc Natl Acad Sci USA 2008 105 5166 5171 18362358 PMC2278188
  58. [59]Bork-Jensen J Scheele C Christophersen DV Nilsson E Friedrichsen M Fernandez-Twinn DS Grunnet LG Litman T Holmstrøm K Vind B Højlund K Beck-Nielsen H Wojtaszewski J Ozanne SE Pedersen BK Poulsen P Vaag A Glucose tolerance is associated with differential expression of microRNAs in skeletal muscle: results from studies of twins with and without type 2 diabetes Diabetologia 2015 58 363 373 25403480 PMC4287682
  59. [60]Rodriguez A Griffiths-Jones S Ashurst JL Bradley A Identification of mammalian microRNA host genes and transcription units Genome Res 2004 14 1902 1910 15364901 PMC524413
  60. [61]Calin GA Sevignani C Dumitru CD Hyslop T Noch E Yendamuri S Shimizu M Rattan S Bullrich F Negrini M Croce CM Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers Proc Natl Acad Sci USA 2004 101 2999 3004 14973191 PMC365734
  61. [62]Chen M Calin GA Meng QH Circulating microRNAs as Promising Tumor Biomarkers Adv Clin Chem 2014 67 189 214 25735862
  62. [63]Di Leva G Croce CM miRNA profiling of cancer Curr Opin Genet Dev 2013 23 3 11 23465882 PMC3632255
  63. [64]Garzon R Calin GA Croce CM MicroRNAs in Cancer Annu Rev Med 2009 60 167 179 19630570

Cited by

Sorted by citations

Authors
Elemeery, M. N., Mohamed, M. A., Madkour, M. A., Shamseya, M. M., Issa, N. M., Badr, A. N., Ghareeb, D. A., & Pan, C.-H.
Affiliations
  • Université de Montréal (CA)
  • Alexandria University (EG)
  • National Research Centre (EG)
  • Korea Institute of Science and Technology (KR)
ORCID
Venue
World Journal of Gastroenterology
Publisher
Baishideng Publishing Group Inc.
Published
2019-11-14
Volume
25
Issue
42
Pages
6322-6341
ISSN
1007-9327 (ISSN-L)
DOI
10.3748/wjg.v25.i42.6322
PMC
PMC6861851
OpenAlex
W2987159487
Cited by
25
References
0
Citations by year
2025: 1 · 2024: 6 · 2023: 2 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 1
FWCI
1.27
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • World Journal of Gastroenterology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Research Centre
  • Korea Institute of Science and Technology (2Z05620)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
hepatocellular carcinoma, type 2 diabetes, microRNA signature, serum microRNA biomarker, liver cirrhosis, nonalcoholic steatohepatitis, cancer screening, miR-34a, miR-221, miR-16, miR-122-5p, miR-198, miR-199a-3p, diagnostic accuracy
MeSH terms
Diabetes Mellitus, Type 2, Female, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Risk Factors, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Case-Control Studies, Disease Progression, MicroRNAs, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review